Last reviewed · How we verify
Atrovastatin and Ezetimibe combination therapy
Inhibits HMG-CoA reductase and inhibits cholesterol absorption
Inhibits HMG-CoA reductase and inhibits cholesterol absorption Used for Hypercholesterolemia, Mixed dyslipidemia.
At a glance
| Generic name | Atrovastatin and Ezetimibe combination therapy |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | HMG-CoA reductase inhibitor and cholesterol absorption inhibitor |
| Target | HMG-CoA reductase and Niemann-Pick C1-Like 1 (NPC1L1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Mechanism of action
Atorvastatin inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, while ezetimibe inhibits the absorption of cholesterol in the small intestine.
Approved indications
- Hypercholesterolemia
- Mixed dyslipidemia
Common side effects
- Muscle pain
- Liver enzyme elevation
- Diarrhea
Key clinical trials
- CKD-391 Pharmacokinetic Study Phase I (PHASE1)
- CKD-391 Pharmacokinetic Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: